ALEXANDRIA, Va., Nov. 6 -- United States Patent no. 12,458,671, issued on Nov. 4, was assigned to BIOPASS (Luxembourg).
"Product for the treatment of dysbiosis" was invented by Daniel Greff (Mere, France).
According to the abstract* released by the U.S. Patent & Trademark Office: "The disclosure relates to a product for topical use in the treatment of skin affected by dysbiosis. The product has a pH ranging from 5.5 to 6.5 and essentially includes water, glycerin and at least one crosslinked polyacrylate. This product can be used as a prerequisite for the transplantation of biological material favorable to the development of a healthy cutaneous bacterial flora."
The patent was filed on Jan. 13, 2020, under Application No. 17/421,154.
*F...